Investigational Drug Information for tomivosertib
✉ Email this page to a colleague
What is the development status for investigational drug tomivosertib?
tomivosertib is an investigational drug.
There have been 6 clinical trials for tomivosertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 12th 2018.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Effector Therapeutics, Stand Up To Cancer, and Translational Research in Oncology.
There are two US patents protecting this investigational drug and twenty-six international patents.
Summary for tomivosertib
| US Patents | 2 |
| International Patents | 26 |
| US Patent Applications | 38 |
| WIPO Patent Applications | 14 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 2 (2018-10-12) |
| Vendors | 49 |
Recent Clinical Trials for tomivosertib
| Title | Sponsor | Phase |
|---|---|---|
| Tomivosertib With Azacitide and Venetoclax for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Suitable for Intensive Chemotherapy | National Cancer Institute (NCI) | Phase 1 |
| Tomivosertib With Azacitide and Venetoclax for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Suitable for Intensive Chemotherapy | Northwestern University | Phase 1 |
| Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 Therapy | Medpace, Inc. | Phase 2 |
Clinical Trial Summary for tomivosertib
Top disease conditions for tomivosertib
Top clinical trial sponsors for tomivosertib
US Patents for tomivosertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| tomivosertib | ⤷ Sign Up | Inhibitors of immune checkpoint modulators and related methods | eFFECTOR Therapeutics Inc. (San Diego, CA) | ⤷ Sign Up |
| tomivosertib | ⤷ Sign Up | Methods and compositions for cellular immunotherapy | eFFECTOR Therapeutics Inc. (San Diego, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for tomivosertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| tomivosertib | Canada | CA3064000 | 2037-05-24 | ⤷ Sign Up |
| tomivosertib | World Intellectual Property Organization (WIPO) | WO2018218038 | 2037-05-24 | ⤷ Sign Up |
| tomivosertib | Australia | AU2015279984 | 2034-06-25 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
